 | *Read Disclaimer Sponsored Content |
| October 2, 2025 | Unsubscribe | Hello! | New Alert: Cosmos Health Inc. (NASDAQ: COSM) | COSM is our brand new NASDAQ high growth alert. | The company has a chart setup positioning for a potential breakout to new highs. | Moreover, it has a recent history of very large moves in a short period of time. | In July, the company rallied from 0.50 to a high of 1.28 in weeks! | Since then, it has experienced incredible volatility and is once again approaching its highs from July. | Over the past week, COSM has been building momentum above 1.10. | This could be setting in motion a big breakout opportunity to new 52-week highs. | In addition, COSM announced multiple accomplishments recently that could be big growth catalysts. | COSM is a NASDAQ listed "diversified, vertically integrated global healthcare group". | COSM owns a "portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®." | Growth in this market is fueled by rising health awareness, demand for natural wellness solutions, and increasing consumer interest in products that support immunity, gut health, cognition, and energy. | With both aging and younger demographics proactively investing in wellness, the U.S. remains the world's largest and most influential nutraceuticals market. | The company's "long-term direction includes, among other priorities": | "Expanding our global reach across Europe, North America, the Middle East, and Asia." "Scaling branded nutraceuticals and pharmaceuticals into globally recognized products." "Building a proprietary therapeutics pipeline with multi-billion-dollar market potential." "Leveraging AI and blockchain to redefine drug discovery, intellectual property monetization, and corporate treasury management." "Delivering sustained shareholder returns through financial innovation, operational excellence, and long-term growth."
| As the company further notes in its most recent shareholder letter from Monday: | "Harnessing a $300 Million Digital Asset Facility to Power Growth & Innovation": | "In August 2025, we secured a financing facility from a U.S. institutional investor in the maximum aggregate principal amount of $300 million in the form of senior secured convertible promissory notes. Under the terms of the notes": | "72.5% of net proceeds from the sale of each note will be directed toward building a digital treasury reserve, including Ethereum (ETH), Bitcoin (BTC), Solana (SOL) and other digital assets." "The balance will be allocated to working capital and to accelerating growth initiatives, both organic and through acquisitions."
| "With capacity to invest over $200 million in digital assets", COSM is "creating one of the largest corporate digital treasury reserves while also retaining significant capital for its core operations". | COSM believes this strategy: | "Provides exposure to the upside of global digital asset adoption, increasingly embraced by governments and institutions." "Strengthens our ability to deploy capital across our various business segments." "Acts both as a diversification tool and a catalyst for growth."
| Through its "subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union." | "Since acquiring Cana in 2023", COSM has "advanced a multi-million-dollar expansion to modernize its wholly owned 54,000-square-foot facility in Athens, Greece, completing Phase I upgrades in 2024". | The company believes "these investments position Cana to generate more than $10 million in recurring annual gross profit at full capacity." | "What makes Cana's transformation particularly compelling is the visibility of its long-term contract pipeline consisting of the following:" | "Pharmex: Five-year agreement for 1.5 million bottles of Ambitasol 1L." "Provident Pharmaceuticals: Order book of 5.02 million units (DE3-SOLE, MIOREL, CALCIFOLIN, DEXA-DOSE, etc.), plus a landmark 10-year contract for 8 million packs across four additional products (Miorelique®, BE Union F.C., and Certorun variations)." "Humacology: Agreement to manufacture up to 500,000 CBD units." "Medical Pharmaquality: Agreement for 3 million MYCOFAGYL® pessaries annually."
| COSM also "distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK". | Furthermore, "the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products." | "Key achievements include": | "Obesity & Metabolic Disorders: Advanced CCX0722 toward clinical evaluation, positioning for entry into the global weight-management market." "Oncology: Acquired full rights to a WIPO-filed CNS cancer patent; filed new AI-driven patents in gliomas and hematologic malignancies with Cloudpharm and the National Hellenic Research Foundation; and secured exclusive worldwide licenses for two patented anticancer therapies targeting prostate, ovarian, and colorectal cancers." "Autoimmune & Neurological Disorders: Expanded pipeline with Cloudscreen-derived candidates for multiple sclerosis and inflammatory conditions." "Allergy Treatments: Initiated preclinical programs on novel allergy therapies."
| COSM has also "entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA". | With a global distribution platform, COSM is "currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK". | In addition, "In 2024", COSM "expanded further into pharmaceuticals with the acquisition of a 10-drug generics portfolio, giving Cosmos Health direct exposure to the $400 billion global generics market". | "This diversification strengthens [their] positioning across multiple healthcare segments, from premium nutraceuticals to essential medicines, and provides a stable platform for sustainable, long-term growth." | COSM has "Six Pillars of Growth": | "Profitability and Cash Flow: Achieving and sustaining positive operating cash flow through disciplined cost management and scaling of high-margin businesses." "Innovation and Intellectual Property: Expanding our R&D pipeline and advancing CCX0722 and oncology candidates, supported by Cloudscreen's AI-driven discovery engine." "Manufacturing Scale: Leveraging dual GMP-certified hubs in Europe and the U.S. to provide global reach, flexibility, and resilience." "Market Development: Expanding Sky Premium Life® and other brands across Europe, the Middle East, North America, and Asia." "Digital Assets and Tokenization: Building one of the largest digital treasuries in healthcare while piloting blockchain-enabled initiatives to enhance efficiency and transparency." "Acquisitions and Partnerships: Pursuing disciplined acquisitions and alliances to broaden distribution, technology, and branded products."
| COSM has announced multiple accomplishments over the past few months: | "Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units" "Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven" "Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech" "Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025"
| In September, alone, the company had several big accomplishments: | "Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units" | Here are some of the company's comments from this press release: | "Greg Siokas, CEO of Cosmos Health, stated: "We are excited to announce our expansion into Oman, further strengthening our presence in the rapidly growing nutraceuticals market across the GCC. This milestone showcases the exceptional quality of our products and the increasing global demand for our Sky Premium Life brand. We expect the agreement to generate significant revenue for Cosmos, supported by Scientific Pharmacy's established retail and distribution network and the rising demand for premium food supplements in Oman."" |
|
| Furthermore, last week, the company announced: | "Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue"
| In addition, the company had another big announcement: | "Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually" | "Greg Siokas, CEO of Cosmos Health, stated: "We are excited to expand our order book with long-term, high-volume commitments, further reinforcing Cana's reputation as a reliable partner in the pharmaceutical industry. This agreement reflects our partner's confidence in Cana's quality, expertise, and state-of-the-art facilities, while MYCOFAGYL represents another step in our strategy to diversify our product offerings. Women's health remains a critical therapeutic area, and this agreement not only strengthens our manufacturing pipeline but also underscores the strong growth momentum of our contract manufacturing business and our ability to secure new high-margin contracts that strengthen our cash flow." |
|
| Most recently, on Monday, the company announced: | | COSM could breakout to new highs. | Make sure to do your own due diligence. | Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, Website, Chart | | Happy Trading! | | SmallCapStocks Team | | Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. | | DISCLAIMER: | You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the "Publisher"). The information (collectively the "Advertisement") disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender's phone number with the word STOP or HELP for help. | The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. | The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. | Owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 10/1/25 for the distribution of this advertisement about COSM dated 10/2/25. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. | You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@SmallCapStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: | www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy | By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. |  |
|
Tidak ada komentar:
Posting Komentar